23 cases of post-IVI endophthalmitis were diagnosed in 23 patients; of them, 11 (48%) were following aflibercept injection, 10 (43%) following bevacizumab injection, 1 (4%) following triamcinolone acetonide injection, and 1 (4%) following dexamethasone intravitreal implant, giving an overall incidence of 0.045% (0.041% following anti-VEGF agents IVIs and 0.364% following steroidal agents IVIs). This evidence concerns the gene VEGFA and endophthalmitis.